Search

News Safe Long-term Treatment of Nasal Symptoms in Patients with Perennial Allergic Rhinitis

In persistent allergic rhinitis, achieving symptom control is often difficult despite pharmacological treatment and minimizing contact with the allergen. Good efficacy in clinical studies has been shown with combined therapy of intranasal antihistamines with locally acting corticosteroids. The presented study evaluated the long-term safety profile and efficacy of a fixed combination of olopatadine with mometasone.

Source: Life Without Allergic Rhinitis 24. 3. 2022

News Benefit of Adding Empagliflozin to Standard Therapy in Heart Failure with Reduced Ejection Fraction

The use of empagliflozin led to a reduction in the risk of hospitalization for heart failure or death from cardiovascular (CV) causes in the EMPEROR-Reduced study in patients with adequately treated heart failure with reduced left ventricular ejection fraction (HFrEF) compared to placebo, regardless of whether the patients had diabetes. A post hoc analysis of this study focused on another important question: how does the benefit of adding empagliflozin interact with the standard disease-modifying therapy for heart failure?

Source: Heart Failure 5. 8. 2022

News Risk Factors and Therapy of Chronic Leg Ulcers Lasting More Than 6 Months

The therapy of chronic leg ulcers in diabetics continues to be a significant challenge for attending physicians and surgeons. Authors of a recently published study have addressed the risk factors, clinical symptoms, and, last but not least, the therapy outcomes of chronic leg ulcers lasting more than 6 months.

Source: Wound Healing 3. 2. 2020

News Selecting from the Red Book CHS: What's New in This Year's Recommendations for the Diagnosis and Treatment of CLL?

Chronic lymphocytic leukemia (CLL) is the most common lymphoid malignancy in adults in Europe and North America. However, this field is experiencing very dynamic developments, both in terms of diagnosis and therapy. The biggest changes have occurred in treatment regimens, and recommendations for the therapy of relapsed or refractory CLL have also changed. Innovations have also emerged in prognostic examinations. As part of the update to the 'Red Book' by the Czech Hematological Society ČLS JEP (CHS), fresh recommendations concerning this disease were published in October 2023.

Source: Chronic Lymphocytic Leukemia 7. 12. 2023

News Prophylaxis EHL products FVIII bring improvements in clinical and pharmacokinetic results

A freshly published real-world clinical practice study from Spain highlights the experience of switching patients with hemophilia A in a prophylaxis setting from standard half-life products to newer products with an extended elimination half-life.

Source: Hemophilia 8. 8. 2022

News Benefits and Cost-Effectiveness of Superabsorbent Dressings in the Treatment of Venous Leg Ulcers

A recent cost-effectiveness analysis based on German data showed that using superabsorbent dressings instead of conventional dressings in the treatment of venous leg ulcers with moderate to high exudation increases the likelihood of healing, quality of life, and reduces direct healthcare costs. Similar results were found in another analysis from last year, this time using French data, comparing superabsorbent dressings with foam dressings, again in the treatment of venous leg ulcers.

Source: Wound Healing 26. 4. 2023

News Register of Patients Treated with Growth Hormone (REPAR): Data Analysis as a Path to Further Optimization of Care

Treatment with recombinant growth hormone (rhGH) is available in the Czech Republic for all children meeting the indication criteria. A network of 10 centers covers the entire country, and all doctors authorized to prescribe growth hormone are united in the Pediatric Growth Hormone Working Group. The Czech national Register of Patients Treated with Growth Hormone (REPAR) has been collecting data on patients treated with rhGH since 2014. The aim of the presented work was to analyze selected data and present the basic demographics of patients included in this database during the first 5 years of its existence.

Source: Growth Disorders 30. 11. 2020

News Impact of Candesartan on Achieving Remission in Patients with Active IgA Nephropathy

IgA nephropathy is the most common glomerulonephritis worldwide and in the Czech Republic. The effect of candesartan (an angiotensin receptor blocker) on the remission of active IgA nephropathy in patients treated with steroid pulses and tonsillectomy was investigated by the randomized study presented below.

Source: Sartans in the Treatment of Hypertension 18. 4. 2020

News Nirmatrelvir/ritonavir reduces the risk of hospitalization for COVID-19 even in the era of predominant omicron subvariants BA.4 and BA.5

One of the first studies to evaluate the efficacy of nirmatrelvir/ritonavir in non-hospitalized patients with COVID-19 infection during the period of predominant omicron variants including subvariants BA.4 and BA.5 has provided real-world data confirming the position of this antiviral in the first line of treatment for patients with mild to moderately severe SARS-CoV-2 infection and a high risk of severe disease.

Source: COVID-19 16. 10. 2023

News Targeted DNA Sequencing Helps Find Targeted Therapy for Patients with NSCLC

Gene sequencing has become a key tool in deciding the treatment for patients with non-small cell lung cancer (NSCLC). At a university in Seoul, South Korea, a retrospective analysis of the benefits of targeted genetic testing in real clinical practice was conducted.

Source: Genetic Profile and Treatment of NSCLC 25. 5. 2020

News Alpha-1-Antitrypsin Deficiency and Its Association with Atopy in Asthmatics

Literature mentions the coincidence of asthma and alpha-1-antitrypsin deficiency, which is caused by a mutation in the SERPINA1 gene. The aim of the study presented below was to determine whether the clinical symptoms of asthma differ between patients with and without this mutation.

Source: Deficiency of Alpha-1-Antitrypsin 14. 5. 2021

Články časopisu Utilization of Prostate Health Index in prediction of prostate cancer aggressiveness

Author of the article: P. Brož, O. Dolejšová, R. Fuchsová, O. Topolčan, J. Racek, H. Sedláčková, O. Hes, V. Eret, L. Pecen, M. Hora, R. Kučera Source: Klinická biochemie a metabolismus | 1/2019 1. 3. 2019

News Risks Associated with Higher Residual Concentrations of Dabigatran in Seniors and Their Prevalence

Dabigatran is a direct thrombin inhibitor indicated for patients across the age spectrum. The benefit-risk assessment of anticoagulation is individual and depends on many factors. A Dutch observational pilot study examined residual concentrations of dabigatran in seniors of different ages with atrial fibrillation to clarify the relationship between study results and clinical practice.

Source: Anticoagulant Treatment 8. 9. 2022

News Population Pharmacokinetic Model in Patients with von Willebrand Disease

Dutch authors presented a potential population pharmacokinetic model describing levels of von Willebrand factor and coagulation factor VIII during and after surgical procedures in patients with von Willebrand disease.

Source: Von Willebrand Disease 14. 11. 2022

News Two Current Perspectives on the Importance of (Par)enteral Nutrition in Cancer Patients

Adequate (par)enteral nutrition is crucial for cancer patients in terms of prognosis and quality of life. The following recent studies examined parenteral nutrition as an alternative to ileostomy in patients with colorectal anastomosis and muscle mass loss in patients with metastatic cancer.

Source: Parenteral Nutrition 14. 11. 2022